-
1.发明申请公开(公告)号：US20070207168A1
公开(公告)日：2007-09-06
申请号：US11553492
申请日：2006-10-27
申请人： Juergen Daemmgen , Eric Vaughn
发明人： Juergen Daemmgen , Eric Vaughn
IPC分类号： A61K39/145
CPC分类号： C07K14/005 , A61K39/12 , A61K39/145 , A61K2039/525 , A61K2039/5252 , A61K2039/5256 , A61K2039/55 , A61K2039/552 , A61K2039/55511 , A61K2039/55555 , A61K2039/55566 , C12N2710/14143 , C12N2760/16122 , C12N2760/16134
摘要： The present invention relates to a method for prevention of the transmission of a pathogen of an animal of a first species to an animal of a second species characterized in that antigen of a pathogen of an animal of a first species is used for the immunization of an animal of a second species against the pathogen of the animal of the first species, wherein the administration of said antigen results in the reduction or the absence of the reproduction of pathogen of the animal of the first species in an animal of the second species.
摘要翻译： 本发明涉及一种预防第一种动物的病原体向第二物种的动物传播的方法，其特征在于将第一种动物的病原体的抗原用于免疫接种 针对第一种动物的病原体的第二物种的动物，其中所述抗原的施用导致在第二物种的动物中第一物种的动物的病原体的繁殖的减少或不存在。
-
2.发明申请NOVEL H5 PROTEINS, NUCLEIC ACID MOLECULES AND VECTORS ENCODING FOR THOSE, AND THEIR MEDICINAL USE 有权新型H5蛋白，核酸分子和编码的载体及其药物使用公开(公告)号：US20080193471A1
公开(公告)日：2008-08-14
申请号：US11923326
申请日：2007-10-24
CPC分类号： A61K39/145 , A61K39/00 , A61K39/12 , A61K2039/53 , A61K2039/55555 , A61K2039/55566 , C07K14/005 , C12N2760/16122 , C12N2760/16134
摘要： The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.
摘要翻译： 本发明涉及新的血凝素H5蛋白，核酸和编码这些蛋白的载体以及包含任何这样的H5蛋白，核酸或编码这些H5蛋白的载体的疫苗。 此外，本发明还涉及任何这样的组合物在人和动物中的药物用途。
-
3.发明授权公开(公告)号：US09375469B2
公开(公告)日：2016-06-28
申请号：US14061249
申请日：2013-10-23
IPC分类号： C07K14/00 , A61K39/145 , C07K14/005 , A61K39/12 , A61K39/00
CPC分类号： A61K39/145 , A61K39/00 , A61K39/12 , A61K2039/53 , A61K2039/55555 , A61K2039/55566 , C07K14/005 , C12N2760/16122 , C12N2760/16134
摘要： The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.
-
4.发明申请Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor 审中-公开包含组合的血栓烷受体拮抗剂和血栓烷合成酶抑制剂和COX-2抑制剂的组合物公开(公告)号：US20060217431A1
公开(公告)日：2006-09-28
申请号：US11276972
申请日：2006-03-20
申请人： Juergen Daemmgen , Joanne van Ryn , Brian Guth , Michel Pairet
发明人： Juergen Daemmgen , Joanne van Ryn , Brian Guth , Michel Pairet
IPC分类号： A61K31/557 , A61K31/365 , A61K31/415
CPC分类号： A61K31/4406 , A61K31/195 , A61K31/5415 , A61K31/63 , A61K45/06 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor. In addition a method of treating cyclooxygenase dependent disorders, including inflammation, pain and/or rheumatic diseases, and/or neoplasia is described.
摘要翻译： 本发明涉及包含组合的血栓烷受体拮抗剂和血栓素合酶抑制剂和COX-2抑制剂的药物组合物。 此外，还描述了一种治疗环氧合酶依赖性疾病，包括炎症，疼痛和/或风湿性疾病和/或瘤形成的方法。
-
5.发明授权公开(公告)号：US08524701B2
公开(公告)日：2013-09-03
申请号：US12139091
申请日：2008-06-13
申请人： Brian Guth , Randolph Seidler , Juergen Daemmgen
发明人： Brian Guth , Randolph Seidler , Juergen Daemmgen
IPC分类号： A61K31/195 , A61K31/55 , A61K45/06
CPC分类号： A61K45/06 , A61K9/0095 , A61K31/195 , A61K31/55 , A61K2300/00
摘要： The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment of heart failure of any aetiology.
摘要翻译： 本发明提供了用于治疗任何病因的心力衰竭的特定环胺衍生物或其药学上可接受的盐的药物组合物中的用途。
-
公开(公告)号：US20130203690A1
公开(公告)日：2013-08-08
申请号：US13832292
申请日：2013-03-15
IPC分类号： A61K31/501 , A61K31/55 , A61K31/341 , A61K31/7048 , A61K31/40
CPC分类号： A61K31/501 , A61K31/341 , A61K31/40 , A61K31/4166 , A61K31/4412 , A61K31/4427 , A61K31/444 , A61K31/55 , A61K31/7048 , A61P9/04
摘要： Phosphodiesterase type III (PDE III) inhibitor or a “Ca2+-sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.
摘要翻译： 磷酸二酯酶III型（PDE III）抑制剂或“Ca 2+敏感剂”或其药学上可接受的衍生物用于制备用于减少患有心力衰竭的患者的心脏尺寸的药物，并且作为用于 无症状（隐匿性）心力衰竭患者心脏的逆向重塑及其延迟的临床症状发作。
-
7.发明申请Use of PDE III Inhibitors For The Treatment of Asymptomatic (Occult) Heart Failure 有权使用PDE III抑制剂治疗无症状（隐匿性）心力衰竭公开(公告)号：US20100035889A1
公开(公告)日：2010-02-11
申请号：US12482481
申请日：2009-06-11
IPC分类号： A61K31/501 , A61K31/50 , A61K31/444 , A61K31/4164 , A61P9/00
CPC分类号： A61K31/501 , A61K31/341 , A61K31/40 , A61K31/4166 , A61K31/4412 , A61K31/4427 , A61K31/444 , A61K31/55 , A61K31/7048 , A61P9/04
摘要： The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having symptomatic or asymptomatic (occult) heart failure.
摘要翻译： 本发明涉及磷酸二酯酶III型（PDE III）抑制剂或Ca2 +敏化剂或其药学上可接受的衍生物用于制备药物的药物的使用，以延长患者的临床症状直到发作为止，无症状（隐匿 ）心力衰竭或有症状或无症状（隐匿性）心力衰竭患者的心脏尺寸减小。
-
8.发明授权公开(公告)号：US08883123B2
公开(公告)日：2014-11-11
申请号：US11553492
申请日：2006-10-27
IPC分类号： A61K49/00 , A61K39/12 , A61K39/145 , C07K1/00 , C07K14/005 , A61K39/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/145 , A61K2039/525 , A61K2039/5252 , A61K2039/5256 , A61K2039/55 , A61K2039/552 , A61K2039/55511 , A61K2039/55555 , A61K2039/55566 , C12N2710/14143 , C12N2760/16122 , C12N2760/16134
摘要： The present invention relates to a method of reducing the transmission of a pathogen from an animal of a first species to an animal of a second species. Specifically, reduction of transmission is accomplished through the administration of antigen of the pathogen such that administration results in the reduction or absence of the reproduction of the pathogen in the animal to which the antigen was administered.
摘要翻译： 本发明涉及一种减少病原体从第一种动物到第二种动物的传播的方法。 具体地，通过施用病原体的抗原来实现透射的减少，使得施用导致在施用抗原的动物中减少或不存在病原体的繁殖。
-
9.发明授权H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use 有权H5蛋白，核酸分子和编码它们的载体及其药物用途公开(公告)号：US08592558B2
公开(公告)日：2013-11-26
申请号：US13476405
申请日：2012-05-21
IPC分类号： C07K1/00 , A61K39/00 , A61K39/145
CPC分类号： A61K39/145 , A61K39/00 , A61K39/12 , A61K2039/53 , A61K2039/55555 , A61K2039/55566 , C07K14/005 , C12N2760/16122 , C12N2760/16134
摘要： The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.
摘要翻译： 本发明涉及新的血凝素H5蛋白，核酸和编码这些蛋白的载体以及包含任何这样的H5蛋白，核酸或编码这些H5蛋白的载体的疫苗。 此外，本发明还涉及任何这样的组合物在人和动物中的药物用途。
-
10.发明申请USE OF BRADYCARDIAC SUBSTANCES IN THE TREATMENT OF MYOCARDIAL DISEASES ASSOCIATED WITH HYPERTROPHY AND NOVEL MEDICAMENT COMBINATIONS 审中-公开在治疗与高血压和新药物组合相关的心肌病的治疗中使用溴氰菊酯物质公开(公告)号：US20070155679A1
公开(公告)日：2007-07-05
申请号：US11684974
申请日：2007-03-12
申请人： Juergen Daemmgen , Brian Guth , Randolph Seidler
发明人： Juergen Daemmgen , Brian Guth , Randolph Seidler
IPC分类号： A61K31/704 , A61K31/455
CPC分类号： A61K31/4184 , A61K31/55 , A61K45/06 , A61K2300/00
摘要： The present invention relates to the new use of bradycardiac substances such as a Ca++ channel blocker, beta-receptor blocker or if channel blocker, the if channel blockers being preferred, optionally in combination with a cardioactive substance for inducing the regression of myocardial diseases accompanied by hypertrophy, particularly for the treatment of idiopathic hypertrophic cardiomyopathies (HCM) in humans and domestic pets.
摘要翻译： 本发明涉及新型使用的心动过缓物质，例如Ca ++通道阻断剂，β-受体阻断剂或I通道阻滞剂，i F 通道阻滞剂是优选的，任选地与用于诱导伴随肥大的心肌疾病消退的心脏活性物质组合，特别是用于治疗人和家养宠物中的特发性肥厚型心肌病（HCM）。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.02 秒)
